Moderate

Seasonal influenza - antiviral treatment

Influenza Rx · Infectious Disease
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Neuraminidase inhibitors (and newer baloxavir) reduce illness duration and complications in influenza, with greatest benefit started within 48 hours. Treat promptly in severe, hospitalised, or high-risk patients regardless of time since onset.

Red flags

  • Hypoxia or respiratory distress
  • Altered mental status
  • Features of secondary bacterial pneumonia or sepsis
  • Haemodynamic instability
  • Rapid deterioration in pregnancy or immunosuppression

Assessment

Differential diagnosis

  • COVID-19
  • Other respiratory viruses (RSV, parainfluenza)
  • Community-acquired bacterial pneumonia
  • Early sepsis
  • Acute exacerbation of COPD/asthma

Investigations

  • Rapid influenza PCR / multiplex respiratory panel
  • Oxygen saturation and respiratory rate
  • Chest radiograph if lower respiratory signs
  • FBC, CRP, renal and liver function in severe cases
  • Blood cultures if sepsis suspected
  • Consider procalcitonin to assess bacterial co-infection

Management

  • Assess severity, risk factors and duration of symptoms
  • Test to confirm influenza and exclude COVID-19
  • Start antivirals immediately in hospitalised/severe/high-risk patients without waiting for results
  • Prescribe oseltamivir first line; use inhaled/IV options where appropriate
  • Give supportive care: oxygen, fluids, antipyretics
  • Assess for and treat bacterial co-infection (e.g. staphylococcal/pneumococcal pneumonia)
  • Isolate with droplet precautions in hospital
  • Offer post-exposure prophylaxis to high-risk close contacts
  • Monitor for deterioration and respiratory failure
  • Review renal function to dose-adjust oseltamivir
  • Encourage vaccination for future seasons
  • Arrange follow-up for high-risk or complicated cases

Drugs & doses

Oseltamivir 75 mg PO twice daily for 5 days (treatment)
Oseltamivir 75 mg PO once daily for 10 days (post-exposure prophylaxis)
Zanamivir 10 mg inhaled twice daily for 5 days (alternative)
Baloxavir marboxil 40-80 mg PO single dose (weight-based, uncomplicated)
Peramivir 600 mg IV single dose (if oral not possible)

Disposition

Outpatient if mild/low-risk; admit for hypoxia, severe disease or co-infection.

Complications & pitfalls

  • Primary viral or secondary bacterial pneumonia
  • ARDS and respiratory failure
  • Myocarditis and exacerbation of chronic disease
  • Encephalopathy (especially children)
  • Secondary Staphylococcus aureus infection

Exam pearls

  • Treat severe/hospitalised influenza even beyond 48 h from onset
  • Oseltamivir needs dose reduction in renal impairment
  • Baloxavir is a single dose but avoid in severe/immunocompromised where data limited
  • Suspect staphylococcal co-infection with rapidly cavitating pneumonia
  • Annual vaccination is the primary prevention

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.